All In Biotech

Drug Trial Radar · NCT04886804

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Beamion LUNG-1: An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of Zongertinib (BI 1810631) as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

554

Planned (sponsor's estimate)

Start

Jul 2, 2021

Primary completion

Feb 29, 2028

Study completion Aug 29, 2029

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to test whether zongertinib can make tumours shrink. In this study, zongertinib is given to people for the first time. Participants take zongertinib as tablets once a day or twice a day. The participants are in the study for as long as they benefit from and can tolerate treatment. Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by zongertinib.

Conditions

  • Neoplasm Metastasis
  • Non-Small Cell Lung Cancer

Interventions

  • zongertinibDrug

    zongertinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: Maximum Tolerated Dose (MTD)Time frame: At the end of Cycle 1 (each cycle is 21 days).
  2. Phase Ia: Number of patients with Dose Limiting Toxicities (DLTs) in the MTD evaluation periodTime frame: At the end of Cycle 1 (each cycle is 21 days).
  3. Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response (OR) as assessed by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  4. Phase Ib - Cohorts 3 (patients prior to CTP v8.0), 6, 7, 8, and 9: Objective response according to RECIST 1.1 by investigator assessmentTime frame: From the start of the trial treatment until end of month 12, up to 12 months.
  5. Phase Ib: Cohort 4: Objective response according to Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) by central independent reviewTime frame: From the start of the trial treatment until end of month 12, up to 12 months.

Locations

85 sites in 18 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Precision NextGen Oncology

    Beverly Hills, California · Completed

  • City of Hope-Duarte-56419

    Duarte, California · Recruiting

  • City of Hope - Seacliff

    Huntington Beach, California · Completed

  • City of Hope-Irvine-69674

    Irvine, California · Completed

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • University of California Irvine

    Orange, California · Recruiting

  • University of California Davis

    Sacramento, California · Recruiting

  • Georgetown University

    Washington D.C., District of Columbia · Recruiting

  • Holy Cross Hospital-Fort Lauderdale-57892

    Fort Lauderdale, Florida · Recruiting

  • Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Hawaii Cancer Care - Honolulu

    Honolulu, Hawaii · Recruiting

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Sarah Cannon Research Institute-Nashville-48456

    Nashville, Tennessee · Recruiting

  • Mary Crowley Cancer Research Center

    Dallas, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Recruiting

  • Macquarie University

    Macquarie Park, New South Wales, Australia · Completed

  • Ordensklinikum Linz GmbH

    Linz, Austria · Completed

  • Brussels - HOSP Jules Bordet

    Anderlecht/Brussels-Capital, Belgium · Active not recruiting

  • Beijing Cancer Hospital

    Beijing, China · Completed

  • Jilin Province Cancer Hospital

    Changchun, China · Completed

  • The First Hospital of Jilin University

    Changchun, China · Active not recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Active not recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, China · Active not recruiting

  • The First Affiliated Hospital, Zhejiang University

    Hangzhou, China · Active not recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Active not recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Active not recruiting

  • The Affiliated Cancer Hospital, Guangxi Medical University

    Nanning, China · Completed

  • Shanghai Chest Hospital

    Shanghai, China · Completed

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China · Active not recruiting

  • Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T

    Wuhan, China · Active not recruiting

  • First Affiliated Hospital of Xiamen University

    Xiamen, China · Completed

  • Henan Cancer Hospital

    Zhengzhou, China · Active not recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China · Active not recruiting

  • Hopital Louis Pradel

    Bron, France · Active not recruiting

  • CTR Leon Berard

    Lyon, France · Active not recruiting

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.